The rIL-27 capability of up-regulating HLA-I and PD-L2 molecules in tumor endothelium was confirmed using three different MMECs that were treated with rIL-27100 ng (or IFN-γ, as control) (Figure 8). This evidence concerns the gene IFNG and neoplasm.